Sotera Health/$SHC
1D1W1MYTD1Y5YMAX
Capital at risk
About Sotera Health
Sotera Health Co provides sterilization, analytical lab testing, and advisory services to help ensure that medical, pharmaceutical, and food products are safe for healthcare practitioners, patients, and consumers. The company operates in three reportable segments: Sterigenics, Nordion, and Nelson Labs. The Sterigenics segment, which generates maximum revenue, provides outsourced terminal sterilization and irradiation services for medical devices, pharmaceuticals, food safety, and other application markets using three core technologies: gamma irradiation, EO processing, and E-beam irradiation. Geographically, the company generates maximum revenue from the United States, followed by Canada, Europe, and other regions.
- Ticker
- $SHC
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 3,000
- Headquarters
- Broadview Heights, United States
- Website
- soterahealth.com
Sotera Health Metrics
BasicAdvanced
$5.3B
32.65
$0.57
1.78
-
Price and volume
Market cap
$5.3B
Beta
1.78
52-week high
$19.85
52-week low
$13.09
Average daily volume
2.5M
Financial strength
Current ratio
2.796
Quick ratio
2.399
Long term debt to equity
3.373
Total debt to equity
3.407
Interest coverage (TTM)
3.34%
Profitability
EBITDA (TTM)
607.243
Gross margin (TTM)
54.97%
Net profit margin (TTM)
13.44%
Operating margin (TTM)
39.33%
Effective tax rate (TTM)
38.10%
Revenue per employee (TTM)
$410,000
Management effectiveness
Return on assets (TTM)
8.60%
Return on equity (TTM)
27.78%
Valuation
Price to earnings (TTM)
32.655
Price to revenue (TTM)
4.336
Price to book
7.94
Price to tangible book (TTM)
-7.6
Price to free cash flow (TTM)
46.792
Free cash flow yield (TTM)
2.14%
Free cash flow per share (TTM)
0.396
Growth
Revenue change (TTM)
8.15%
Earnings per share change (TTM)
570.85%
3-year revenue growth (CAGR)
7.60%
3-year earnings per share growth (CAGR)
-16.02%
What the Analysts think about Sotera Health
Analyst ratings (Buy, Hold, Sell) for Sotera Health stock.
Analyst projections of the future price of Sotera Health stock.
Bulls say / Bears say
Q2 2026 net revenues rose 9.2% year-over-year to $321.38 million (8.0% CC), net income jumped to $54 million from $8 million, Adjusted EBITDA grew 10.0% CC, and management raised its full-year 2026 net revenues growth outlook to 5.25%–6.75% and Adjusted EBITDA growth to 5.75%–7.25%. (GlobeNewswire, Reuters)
Sterigenics expanded its Haw River, NC campus with a new state-of-the-art X-ray sterilization facility in April 2026, boosting irradiation capacity to meet growing customer demand. (Sterigenics)
Sotera Health improved its leverage profile, reducing net debt to Further Adjusted EBITDA from 5.7x in Q1 2025 to 5.0x by Q1 2026 with $5.5 billion of available liquidity, and achieving a net leverage ratio of 3.0x as of June 30 2026. (Sotera Health Business Update, GlobeNewswire)
As of February 20 2026, approximately 305 lawsuits alleging improper EO emissions were filed against Sterigenics subsidiaries in Georgia trial courts, posing ongoing legal liabilities despite indemnifications. (2025 Annual Report)
The company carried $2.2 billion of debt against only $357 million of unrestricted cash as of June 30 2026, with a debt/equity ratio of 3.19, exposing Sotera Health to refinancing and interest rate risks. (GlobeNewswire, MacroTrends)
Nordion’s Cobalt-60 supply is subject to nuclear reactor maintenance and lifecycle risks, exemplified by the planned decommissioning of the Pickering reactor, which could lead to short-term supply constraints and revenue volatility. (Earnings Call Transcript)
Data summarised monthly by Lightyear AI. Last updated on 2 Sept 2026.
Sotera Health Financial Performance
Revenues and expenses
Sotera Health Earnings Performance
Company profitability
Upcoming events
No upcoming events
Sotera Health News
AllArticlesVideos
Funds containing Sotera Health
AllUSDGBPEUR
Fund name | Fund size | $SHC weighting |
|---|---|---|
SPDR S&P 400 US Mid Cap$SPY4 | $6.3B | 0.14% |
SPDR S&P 400 US Mid Cap£SPX4 | £4.7B | 0.14% |
iShares MSCI USA Small Cap ESG Enhanced CTB€SXRG | €2.8B | 0.07% |
iShares MSCI USA Small Cap CTB Enhanced ESG£CUS1 | £2.4B | 0.07% |
iShares MSCI World Small Cap$WSML | $9B | 0.05% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.